Jump to section
To transform the way biological research and analyses are performed, allowing scientists to focus on what they do best - pushing the boundaries of biology.
-3% employee growth in 12 months
The world has undergone a genomic revolution. What the entire world could not do two decades ago - sequence a human genome - a scientist can easily do today and the adoption of sequencing technology is continuing to rapidly increase. Despite these ongoing advancements, preparing samples for sequencing remains a bottleneck, with scientists being held back by existing solutions for sample preparation.
Disruptive innovation is required in order to unlock the true utility of genomics and Volta Labs is taking on that challenge. The Massachusetts-based company is creating a programmable approach to DNA sample preparation with a platform that is providing simple, flexible, and powerful solutions.
What started as a simple graduate project quickly evolved into building biological automation from the ground up. Volta has seen steady growth since its inception in 2018. With the backing of several investment organizations, the company has launched its product to the public and is partnering with genomics tech companies to perfect its sequencing software.
Steph
Company Specialist at Welcome to the Jungle
Jan 2024
$4.3m
EARLY VC
Mar 2022
$20m
SERIES A
This company has top investors
Udayan Umapathi
(CEO)Previously worked as a Research Assistant at MIT Media Lab and Purdue University.
Software Engineering